Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence (ARIADNE)
This study has been completed.
Sponsor:
AstraZeneca
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01081509
First received: March 4, 2010
Last updated: November 15, 2011
Last verified: November 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of this study is to assess the patient's perception about and willingness to take his or her medication and the influencing factors interfering with taking medication.
Condition |
---|
Breast Cancer |
Study Type: | Observational |
Study Design: | Observational Model: Cohort Time Perspective: Prospective |
Official Title: | Survey and Follow-up of the Treatment Adherence and Medication Habits of Early Breast Cancer Patients on Adjuvant Hormonal Therapy With the Aromatase Inhibitor Arimidex |
Resource links provided by NLM:
Genetics Home Reference related topics:
breast cancer
Drug Information available for:
Anastrozole
U.S. FDA Resources
Further study details as provided by AstraZeneca:
Primary Outcome Measures:
- Percent of patients remaining adherent to therapy with Arimidex [ Time Frame: Every 3 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Questionnaire for factors influencing adherence [ Time Frame: Every 3 months ] [ Designated as safety issue: No ]
Enrollment: | 1077 |
Study Start Date: | March 2010 |
Study Completion Date: | October 2011 |
Primary Completion Date: | October 2011 (Final data collection date for primary outcome measure) |
Eligibility
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Study Population
Early breast cancer patients on adjuvant aromatase inhibitor
Criteria
Inclusion Criteria:
- Early breast cancer
- Post menopausal
- Adjuvant hormonal Arimidex therapy
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01081509
Locations
Hungary | |
Research Site | |
Balatonfoldvar, Hungary | |
Research Site | |
Bekescsaba, Hungary | |
Research Site | |
Budapest, Hungary | |
Research Site | |
Debrecen, Hungary | |
Research Site | |
Dombovar, Hungary | |
Research Site | |
Gyongyos, Hungary | |
Research Site | |
Gyor, Hungary | |
Research Site | |
Gyula, Hungary | |
Research Site | |
Kaposvar, Hungary | |
Research Site | |
Kecskemet, Hungary | |
Research Site | |
Miskolc, Hungary | |
Research Site | |
Mosdos, Hungary | |
Research Site | |
Nagyatad, Hungary | |
Research Site | |
Nyiregyhaza, Hungary | |
Research Site | |
Orfu, Hungary | |
Research Site | |
Papa, Hungary | |
Research Site | |
Pecs, Hungary | |
Research Site | |
Szeged, Hungary | |
Research Site | |
Szekesfehervar, Hungary | |
Research Site | |
Szekszard, Hungary | |
Research Site | |
Szentes, Hungary | |
Research Site | |
Szombathely, Hungary | |
Research Site | |
Veszprem, Hungary | |
Research Site | |
Zalaegerszeg, Hungary | |
Research Site | |
Zirc, Hungary |
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: | Zsolt Horvath, M.D., Ph.D. | Hungarian National Institute of Oncology |
More Information
No publications provided
Keywords provided by AstraZeneca:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 17, 2012
No publications provided
Responsible Party: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT01081509 History of Changes |
Other Study ID Numbers: | NIS-OHU-ARI-2010/1 |
Study First Received: | March 4, 2010 |
Last Updated: | November 15, 2011 |
Health Authority: | Hungary: National Institute of Pharmacy |
Keywords provided by AstraZeneca:
adherence early breast cancer Arimidex Therapy adherence |
Additional relevant MeSH terms:
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Anastrozole Aromatase Inhibitors |
Antineoplastic Agents, Hormonal Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on October 17, 2012